Monocytohigh-density lipoprotein ratio has a high predictive value for the diagnosis of multiple system atrophy and the differentiation from Parkinson’s disease

Lijuan Jiang¹, Zhen Zhong¹, Juan Huang¹, Hetao Bian²* and Wei Huang¹*

¹Department of Neurology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ²Department of Neurology, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China

Background and purpose: Inflammation is closely related to the pathogenesis of multiple system atrophy (MSA). As markers of inflammation, the monocyte to high-density lipoprotein ratio (MHR), neutrophil to lymphocyte ratio (NLR), and red cell distribution width to platelet ratio (RPR) have been proven to be associated with a large variety of diseases. The aim of this study was to explore the association between inflammatory markers (MHR, NLR, and RPR) and MSA, and the difference between MSA and Parkinson’s disease (PD) was further compared by these inflammatory markers.

Materials and methods: This study was divided into three groups: 47 patients with MSA, 125 patients with PD, and 124 healthy controls. The corresponding laboratory indicators of subjects were collected and analyzed to obtain MHR, NLR, and RPR values.

Results: Compared with healthy controls, the MHR, NLR, and RPR were higher in the MSA group (\(P < 0.05\)), and the MHR was higher in the MSA group than in the PD group (\(P < 0.001\)). Multivariate logistic regression analysis showed that MHR*10 (corrected OR = 1.312, 95% CI 1.093–1.575) and RPR*100 (corrected OR = 1.262, 95% CI 1.055–1.509) were positively correlated with the risk of MSA. The receiver operating characteristic (ROC) curve indicated that the areas under the curve (AUCs) for predicting MSA were 0.651 (95% CI 0.562–0.74; \(P < 0.05\)), 0.6 (95% CI 0.501–0.699; \(P < 0.05\)), and 0.612 (95% CI 0.516–0.708; \(P < 0.05\)), respectively. The AUC of MSA and PD predicted by the MHR was 0.727 (\(P < 0.001\)). When the cut-off value was 0.38, the sensitivity and specificity were 60 and 77%, respectively. Spearman correlation analysis showed that the MHR was significantly and positively correlated with the course of MSA cerebellar type (MSA-C) patients.
Conclusion: There may be peripheral inflammation in patients with MSA. Compared with NLR and RPR, MHR has higher predictive value for the diagnosis and differential diagnosis of MSA.

KEYWORDS
multiple system atrophy, Parkinson’s disease, monocyte to high-density lipoprotein ratio, neutrophil to lymphocyte ratio, red cell distribution width to platelet ratio, peripheral inflammation

Introduction

Known as multiple system atrophy (MSA), this neurodegenerative condition affects multiple systems. MSA is a disease that causes Parkinsonian symptoms as well as cerebellar and autonomic dysfunction, with various clinical manifestations. MSA falls into two categories: multiple system atrophy-parkinsonism (MSA-P) and multiple system atrophy-cerebellar ataxia (MSA-C) (Fanciulli and Wenning, 2015). Some scholars have found that the incidence rate of MSA is 0.11/1,00,000 person-years, which is relatively rare (Winter et al., 2010). The pathology of MSA involves deposition of \( \alpha \)-synuclein (\( \alpha \)-synuclein). Parkinson’s disease (PD) is another neurodegenerative disease, and its pathological changes are mainly related to the deposition of \( \alpha \)-synuclein. Both PD and MSA belong to \( \alpha \)-synucleinopathy. At present, a study has confirmed the correlation between PD and peripheral inflammation. When the level of peripheral inflammation increases, microglia may sense changes in the peripheral environment, and release reactive oxygen species and cytokines, activating astrocytes, oligodendrocytes, and vascular endothelial cells to further release inflammatory factors, accelerating the aggregation of \( \alpha \)-synuclein and ultimately leading to neuronal damage (Subeta et al., 2021).

The pathogenesis of MSA is unclear, and neuroinflammation may be one of them. Harms et al. (2021) confirmed that elevated proinflammatory factors and T lymphocyte invasion were found in the cerebrospinal fluid of MSA patients and animal models. Williams et al. (2020) observed the proliferation and activation of inflammatory microglia and peripheral monocytes in the central nervous system (CNS) in MSA mouse models. The above studies mainly focused on the CNS, while there are few studies on peripheral inflammation in MSA, and there are no consistent conclusion. The neutrophil to lymphocyte ratio (NLR), monocyte to high-density lipoprotein ratio (MHR), and red cell distribution width to platelet ratio (RPR) are novel indicators of peripheral inflammation. For the past few years, studies have indicated that they are involved in tumors, cardiovascular diseases, and neurodegenerative diseases such as PD and progressive supranuclear palsy (PSP) (Inci et al., 2020; Li et al., 2021; Liu et al., 2021). Inflammation is involved in the pathogenesis of MSA. Additionally, both MSA and PD belong to \( \alpha \)-synucleinopathy, showing similar pathological changes. Is there a similar relationship between MSA and peripheral inflammation? This study aims to explore the relationship between MSA and peripheral inflammation from the perspective of novel indicators of peripheral inflammation. As MSA only presents with Parkinsonian-like symptoms in the early stage, it is difficult to distinguish from PD. To provide clinical clues between MSA and PD for early identification, we further analyzed the differences in novel inflammatory indicators.

Materials and methods

We collected the data of 172 patients hospitalized in the Department of Neurology of the Second Affiliated Hospital of Nanchang University from January 2016 to May 2022, including 47 patients with MSA and 125 patients with PD. Based on the Consensus of the American Academy of Neurology, the diagnosis was possible MSA (Gilman et al., 2008). MDS clinical diagnostic criteria were adopted to diagnose PD (Postuma et al., 2015). A total of 124 age- and sex-matched healthy patients were selected as the control group. Patients with the following diseases were excluded: (1) neurodegenerative diseases such as progressive supranuclear palsy, corticobasal degeneration, Lewy body dementia, front temporal dementia, and Alzheimer’s disease; (2) diabetes, hypothyroidism, tumors, and autoimmune diseases; (3) infection; (4) acute stroke; (5) liver or renal failure; and (6) use of hypolipidaemic drugs.

This study was a retrospective study and was approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University.

General information of all patients was recorded, including age, gender, disease duration, past medical history, tobacco and alcohol use and medication history, and family history. NLR, MHR, and RPR values were calculated by recording neutrophils, lymphocytes, monocytes, red cell distribution width, platelets (PLTs), and high-density lipoprotein (HDL) values. The units of neutrophils, monocytes, lymphocytes,
Risk factor analysis for multiple system atrophy

Multivariate logistic regression analysis showed that MHR*10 (corrected OR = 1.312, 95% CI 1.093–1.575) and RPR*100 (corrected OR = 1.262, 95% CI 1.055–1.509) were positively correlated with the risk of MSA, as shown in Table 2.

Receiver operating characteristic curve analysis

We evaluated the predictive value of the MHR, NLR, and RPR for MSA, and the AUCs of the MHR, NLR, and RPR were 0.651, 0.6, and 0.631, respectively (P < 0.05) (Figure 1). The cut-off value for the MHR was 0.3, for which the sensitivity for the prediction of MSA was 75% and the specificity was 52% (95% CI 0.562–0.74).

The AUC of MHR combined with NLR and RPR was 0.688 (P < 0.001). When the cut-off value was 0.22, it predicted MSA with 77% sensitivity and 52% specificity (95% CI 0.604–0.771).

The AUC of MSA and PD predicted by MHR was 0.727, with a sensitivity of 60% and specificity of 77% (95% CI: 0.644–0.81, P < 0.001), when the cut-off value was 0.38 (Figure 2). The data are shown in Table 3.

Spearman correlation analysis

We analyzed the correlation between the MHR, NLR, and RPR and disease duration in different types of MSA patients. The results suggested that the MHR was significantly and positively correlated with the course of MSA-C (Table 4). The baseline data of different types of MSA are shown in Appendix 1.

Discussion

The etiology of MSA is unclear, and its possible mechanism is related to intracellular oxidative stress and inflammation caused by abnormal aggregation of α-synuclein. A number of studies have demonstrated that central inflammation exists in both MSA models and patients. Furthermore, neuroinflammation accelerates neuronal cell death (Fanciulli and Wenning, 2015). For example, Hofmann et al. (2019) found in a mouse model of MSA that increased gene expression of proinflammatory cytokines was detected in oligodendrocytes overexpressing α-synuclein. This may be related to the proliferation and activation of myeloid cells caused by oligodendrocyte overexpression of α-synuclein, thus

Results

Comparison of baseline data and laboratory indicators among the three groups

In the MSA group, there were 47 cases, including 30 males (63.8%), with an age of 61 years (55–66). Among 125 PD patients, 72 (57.6%) were males, with an age of 63 years (56–68). There were 124 healthy controls, including 60 males (48.4%), with an age of 58 years (52–67.75). There were no significant differences in age, sex, smoking, drinking or hypertension among the three groups (P > 0.05). Compared with the HC group, the MHR, NLR, RPR, and monocytes of the MSA group were higher, the distribution width of erythrocytes and HDL were lower, and the differences were statistically significant. Compared with the HC group, the RPR and red blood cell distribution width (RDW) were higher in the PD group (P < 0.05), and the neutrophils, monocytes, lymphocytes, PLTs, and MHR were lower (P < 0.05). The MSA group had higher levels of MHR, neutrophils, and monocytes and lower levels of HDL than the PD group (P < 0.05). The results are presented in Table 1.
TABLE 1 | Comparison of baseline data and laboratory indicators among the three groups.

|                  | MSA (n = 47) | PD (n = 125) | HC (n = 124) | Z1/χ1/T1 | Z2/χ2/T2 | Z3/χ3/T3 |
|------------------|--------------|--------------|--------------|----------|----------|----------|
| Age (years)      | 61 (55–66)   | 63 (56–68)   | 58 (52–67.75) | −0.28    | 0.779    | −1.907   |
| Sex (male, %)    | 30 (63.8%)   | 72 (57.6%)   | 60 (48.4%)   | 3.36     | 0.807    | 2.121    |
| Smoking (%)      | 5 (10.6%)    | 10 (8%)      | 12 (9.7%)    | 0.035    | 0.851    | 0.271    |
| Drinking (%)     | 7 (14.9%)    | 12 (9.6%)    | 8 (6.5%)     | 3.035    | 0.081    | 0.835    |
| Hypertension (%) | 12 (25.5%)   | 19 (15.2%)   | 26 (21%)     | 0.411    | 0.522    | 1.399    |
| Hyperlipidemia (%)| 8 (17%)     | 19 (15.2%)   | 22 (17.7%)   | 0.12     | 0.912    | 0.292    |
| CHD (%)          | 1 (2.1%)     | 2 (1.6%)     | 0 (0%)       | /        | 0.275    | /        |
| Family history (%)| 1 (2.1%)     | 2 (1.6%)     | 1 (0.8%)     | 0        | 1        | 0        |
| Antiplatelet drugs (%) | 3 (6.4%) | 8 (6.4%) | 13 (10.5%) | 0.279 | 0.598 | 1.344 |
| Monocytes (×10^9/L) | 0.45 ± 0.13 | 0.34 ± 0.13 | 0.39 ± 0.12 | 2.54 | 0.012 | −2.847 |
| HDL-C (×10^9/L) | 1.12 ± 0.325 | 1.25 ± 0.309 | 1.29 ± 0.386 | −2.615 | 0.01 | −0.884 |
| Neutrophils (×10^9/L) | 3.84 | 3.16 | 3.48 | −1.467 | 0.142 | −2.067 |
| Lymphocytes (×10^9/L) | 1.68 ± 0.549 | 1.58 ± 0.481 | 1.76 ± 0.491 | −0.866 | 0.388 | −2.847 |
| RDW-SD (cv, %)   | 12.9         | 13.0         | 12.6         | −2.559   | 0.011   | −3.421   |
| Platelets (×10^12/L) | 197.49 ± 56.67 | 194 (169–230) | 212.48 ± 55.77 | −1.562 | 0.12 | −2.12 |
| MHR              | 0.41         | 0.27         | 0.29         | −3.045   | 0.002   | −2.078   |
| NLR              | 2.22         | 1.96         | 1.95         | −2.007   | 0.045   | −0.582   |
| RPR              | 0.07         | 0.07         | 0.06         | −2.261   | 0.024   | −2.703   |

 PARKINSON'S DRUGS

| Compound levodopa (%) | 18 (38.3%) | 119 (96.7%) | / | / | / | / | 74.266 |
| DR agonist (%)        | 4 (8.5%)   | 80 (64.0%)  | / | / | / | / | 39.9   |
| MAO-B inhibitors (%)  | 3 (6.4%)   | 17 (13.6%)  | / | / | / | / | 1.1    |
| COMT inhibitors (%)   | 0 (0%)     | 6 (3.5%)    | / | / | / | / | /     |
| Anticholinergic drugs (%) | 1 (2.1%) | 18 (14.4%) | / | / | / | / | 4.061 |
| Amantadine (%)        | 1 (2.1%)   | 11 (8.8%)   | / | / | / | / | 1.428 |

MSA, multiple system atrophy; PD, Parkinson’s disease; HC, healthy controls; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; RDW-SD, red cell distribution width; MHR, monocyte to HDL ratio; NLR, neutrophil to lymphocyte ratio; RPR, red cell distribution width to platelet ratio. 1, MSA vs. HC; 2, PD vs. HC; 3, MSA vs. PD.

TABLE 2 | Univariate and multivariate logistic regression analysis of multiple system atrophy (MSA) risk factors.

|                  | Multivariate logistic regression analysis |
|------------------|------------------------------------------|
|                  | Crude OR (95% CI) | P       | Adjusted OR (95% CI) | P       |
| NLR              | 1.184 (0.907–1.547) | 0.215   | –                    | –       |
| MHR*10           | 1.284 (1.078–1.529) | 0.005   | 1.313 (1.093–1.575) | 0.004   |
| RPR*100          | 1.232 (1.04–1.459)  | 0.016   | 1.262 (1.055–1.509) | 0.011   |

Since the values of MHR and RPR are a×10^−1 and b×10^−2, respectively (0 < a < 10, 0 < b < 10). Carry out logistic regression analysis. When the independent variable is increased by 1 unit, the MHR value is equivalent to expanding by 10 times, and the RPR value is equivalent to expanding by 100 times. The obtained OR value will be amplified. Therefore, MHR*10 and RPR*100 conversion are made.

resulting in the proliferation of microglial cells and infiltration of macrophages. Surveys such as those conducted by Yamasaki et al. (2017) showed that cytokines with proinflammatory, anti-inflammatory, and chemotactic effects in the cerebrospinal fluid of patients with MSA were significantly increased, such as IL-6, IL-7, IL-12, IL-13, and GM-CSF. This is similar to the findings of Compta et al. (2019). Studies on autopsy and biopsy of MSA patients have suggested that inflammatory factors increase in brain parenchyma, which may be related to the proliferation of microglia caused by neuron damage and the
release of inflammatory factors (Rydbirk et al., 2017; Li et al., 2018). However, is peripheral inflammation also involved in the pathogenesis of MSA? At present, there are few relevant studies and inconsistent views. In, Kaufman et al. (2013) first explored peripheral inflammatory indicators [IL-6, IL-2, C-reactive protein (CRP), and TNF-α] in the serum of MSA patients, and the study confirmed that the levels of IL-6 and TNF-α in MSA patients were significantly higher than those in the control group. In contrast, similar studies conducted by Kim et al. (2019) did not yield the same results. Taken together, the relationship between MSA and peripheral inflammation needs to be further studied.

Monocytes can induce the production of cytokines with proinflammatory effects, such as TNF and IL-10, and have high antigen-presenting activity, participating in activation and phagocytosis in the inflammatory process (Ziegler-Heitbrock, 2007). Moreover, studies have shown that monocyte chemotactic protein (MCP-1), which plays a role in monocyte recruitment, is significantly increased in the cerebrospinal fluid of MSA patients (Magdalinou et al., 2015). HDL is a kind of plasma lipoprotein that can transport cholesterol to reduce lipid accumulation and has anti atherosclerotic effects. It was reported that HDL could inhibit the activation of white blood cells, neutrophils, and monocytes and played an anti-inflammatory role (Murphy et al., 2009). HDL-C has an antioxidant function by inhibiting the deposition of toxic proteins, and can be used as a protective factor for the onset of MSA (Lee et al., 2009). Therefore, there may be a link between the ratio of HDL to monocytes and inflammation. In recent years, studies have shown that the MHR can be used as an inflammatory indicator to predict the mortality of mesenteric artery embolism, the mortality of acute ischemic stroke within 1 month and the recurrence rate of atrial fibrillation after radiofrequency ablation (Bolayir et al., 2018; Chen et al., 2020; Kuvvetli and Avci, 2020). Considering that inflammation plays a significant role in the pathophysiological process and prognosis of synucleinopathy, such as MSA and PD, we explored the relationships among MHR, MSA, and PD. The results showed that, in terms of MHR, the MSA group and PD group were significantly higher than the HC group, which may be related to the fact that both MSA and PD belong to α-synucleinopathy. Studies have shown that inflammation is involved in the pathogenesis of α-synucleinopathy (La Vitola et al., 2021). In addition, the MHR level of MSA was significantly higher than that of PD, suggesting a higher level of inflammation in MSA. In fact, as a Parkinson-plus syndrome, MSA involves multiple systems and has a more complex pathological mechanism than PD. Therefore, the level of inflammatory factors may be more prominent. In most cases, we can also observe that MSA patients have more serious clinical manifestations and worse prognoses than PD patients (Schapira et al., 1992; Benecke et al., 1993).

Neutrophils and lymphocytes are important indicators of inflammation and are linked to the occurrence, progression, and severity of inflammation. Some studies have shown that the secretion of IL-2 and IL-15, which are involved in T lymphocyte maturation, is significantly increased in the serum
of patients with MSA. In addition, the numbers of CD3 + T lymphocytes and CD4 + T lymphocytes were increased in the peripheral blood of MSA patients (Csencsits-Smith et al., 2016; Cao et al., 2020). The NLR, the ratio between neutrophils and lymphocytes, is considered as a subclinical inflammatory index in European and American countries and can reflect the intensity of inflammation (Azab et al., 2014). Studies have reported associations between NLR and systemic inflammation in a variety of diseases. It has previously been reported that NLR may reflect the peripheral inflammatory processes associated with Alzheimer’s disease (Rembach et al., 2014). A study on peripheral inflammation in patients with PSP found that NLR was associated with PSP but not with PD, which can be used as a predictor to distinguish PSP from PD (Inci et al., 2020). In our study, there was no statistically significant difference in NLR between the PD group and the control group, which was inconsistent with the research results of Liu et al. (2021). A possible explanation for this might be that the PD population included by Liu is located in Qinghai Province at a high altitude. The environment, especially under low oxygen conditions, is an important factor affecting the occurrence and development of PD. Hypoxia can lead to oxidative stress, increase the proinflammatory process and aggravate neuronal injury (Leston et al., 2021). In addition, the special geographical environment of low oxygen and low air pressure in high-altitude areas will cause disorders of human metabolism and immune function. Studies have shown that there is a statistically significant difference in leukocytes between people living in high- and low-altitude areas for a long time, which is the result of immune system regulation (Alkhalidy et al., 2020). Therefore, the correlation between NLR and PD needs to be further verified by a multicenter study. However, the NLR value of the MSA group was higher than that of the healthy control group (P < 0.05), suggesting a correlation between MSA and NLR. MSA may have peripheral inflammation.

Red blood cell distribution width is an indicator of the variability of red cell volume in blood. Studies have shown that inflammatory factors inhibit erythrocyte maturation by reducing the sensitivity of hematopoietic stem cells to erythropoietin (EPO) (Forhecz et al., 2009). Previous studies Solak et al. (2014) revealed a strong positive correlation between RDW and CRP. PLTs are involved in inflammatory processes by mediating leukocyte adhesion and extravasation (Klinger and Jelkmann, 2002; Polak et al., 2020). Thrombocytosis is an indicator of an increased degree of suppurative infection (Tchebiner et al., 2011). In recent years, RPR, as a new inflammatory indicator, has been proven to be a predictive indicator to distinguish hepatic fibrosis from cirrhosis, the severity of cirrhosis, and the 3 months survival rate after thrombectomy for acute cerebral infarction (Chen et al., 2013; Wang et al., 2016; Li et al., 2021). However, there are no relevant studies on RPR in neurodegenerative diseases. The findings of this study suggested that compared with the HC group, the RPR of the MSA group and PD group was higher (P < 0.05), while the platelet counts of the MSA group and PD group was lower. Previous studies have found that the activity of enzymes involved in the oxidative respiratory chain in PLTs of PD patients is reduced by half, resulting in decreased ATP production, which may affect platelet growth or proliferation.

This study explored the relationship between MSA and peripheral inflammatory markers (NLR, MHR, and RPR). The results of this study confirmed the correlation between MSA and peripheral inflammation and further provided evidence that peripheral inflammation was involved in the pathogenesis of MSA. However, limitations exist in this study. First, our study was a retrospective study. The time points of blood samples collected in the included population were different. Additionally, our study was a single-center study. The incidence of MSA is relatively low, and the number of MSA patients

| Indicator      | AUC  | Sensitivity (%) | Specificity (%) | 95% CI          | P   | Cut-off |
|----------------|------|-----------------|-----------------|-----------------|-----|---------|
| MSA vs. HC     | MHR  | 0.651           | 0.750           | 0.520           | 0.562-0.740 | 0.002  | 0.300   |
|                | NLR  | 0.600           | 0.320           | 0.880           | 0.501-0.699 | 0.045  | 2.990   |
|                | RPR  | 0.612           | 0.810           | 0.400           | 0.516-0.708 | 0.024  | 0.060   |
|                | Combination | 0.688   | 0.770           | 0.520           | 0.604-0.771 | <0.001 | 0.220   |
| MSA vs. PD     | MHR  | 0.727           | 0.600           | 0.770           | 0.644-0.810 | <0.001 | 0.380   |

| Disease duration of MSA-C | Disease duration of MSA-P |
|---------------------------|---------------------------|
| ρ  | P   | ρ  | P   |
| MHR | 0.43 | 0.025 | -0.371 | 0.107 |
| NLR | 0.39 | 0.342 | -0.151 | 0.526 |
| RPR | 0.008 | 0.97 | -0.235 | 0.319 |
included is small. Moreover, the diagnosis of MSA is exclusive. However, typical clinical manifestations and pontine “hot cross bun sign” contribute to the diagnosis of MSA. Nevertheless, a considerable number of early stage patients do not show significant clinical characteristics. Specialists with rich clinical experience in motion disorders are also often unable to accurately identify them. Thus, there may be selection bias. In view of the fact that the sensitivity and specificity of the indicators in this study are not very high, it may be necessary to combine with the common autonomic symptoms of multiple system atrophy such as postural hypotension and urinary symptoms in subsequent studies in order to improve the sensitivity and specificity of the testing index. In addition, in subsequent studies, it is also necessary to strictly and accurately control the diagnostic criteria and include adequate sample sizes in prospective and multicenter studies.

Conclusion

In conclusion, peripheral inflammation is correlated with MSA and is connected with the onset of MSA. The study further confirmed that MSA may be higher than PD at the level of inflammation. In addition, the MHR may be used as an indicator of differential diagnosis between MSA and PD. It has certain clinical value and significance. However, despite the presence of peripheral inflammation in MSA, it is not clear whether inflammation is a trigger or a consequence of MSA. The specific related pathways remain unclear and need to be further explored by basic research.

Data availability statement

The original contributions presented in this study are included in the article-supplementary material, further inquiries can be directed to the corresponding authors.

References

Alkhaldy, H. Y., Awan, Z. A., Abouzaid, A. A., Elbahaey, H. M., Al Amoudi, S. M., Shehata, S. F., et al. (2020). The prevalence of isolated neutropenia at high altitude in southern saudi arabia: Does altitude affect leucocyte count?. Int. J. Gen. Med. 13, 1373–1379. doi: 10.2147/IGM.S528433

Azab, B., Camacho-Rivera, M., and Taioli, E. (2014). Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects. PLoS One 9:e112361. doi: 10.1371/journal.pone.0112361

Benecke, R., Strumpner, P., and Weiss, H. (1993). Electron transfer complexes I and IV of platelets are abnormal in Parkinson’s disease but normal in Parkinson-plus syndromes. Brain 116, 1451–1463. doi: 10.1093/brain/116.6.1451

Bolayir, A., Gokce, S. F., Cigdem, B., Bolayir, H. A., Yildiz, O. K., Bolayir, E., et al. (2018). Monocyte/high-density lipoprotein ratio predicts the mortality in ischemic stroke patients. Neurol. Neurochir. Pol. 52, 150–155. doi: 10.1016/j.pjnp.2017.08.011

Cao, B., Chen, X., Zhang, L., Wei, Q., Liu, H., Feng, W., et al. (2020). Elevated Percentage of CD3(+) T-Cells and CD4(+)CD8(+) Ratios in Multiple System Atrophy Patients. Front. Neurol. 11:658. doi: 10.3389/fneur.2020.00658

Chen, B., Ye, B., Zhang, J., Ying, L., and Chen, Y. (2013). RDW to platelet ratio: A novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS One 8:e68780. doi: 10.1371/journal.pone.0068780

Chen, S. A., Zhang, M. M., Zheng, M., Liu, F., Sun, L., Bao, Z. Y., et al. (2020). The preablation monocyte/ high density lipoprotein ratio predicts the late recurrence of paroxysmal atrial fibrillation after radiofrequency ablation. BMC Cardiovasc. Disord. 20:401. doi: 10.1186/s12872-020-01670-3
PLoS One (2013). Proinflammatory cytokines are elevated in serum of patients with multiple system atrophy. Y. H. (2009). Serum cholesterol levels and the risk of multiple system atrophy: “what HIF?”.

Hypoxia signaling in parkinson’s disease: There is use in asking “what HIF?”.

Retrospective study.

Herbecz, Z., Gombos, T., Borgia, G., Pozsonyi, Z., Prohaszka, Z., and Janoskuti, L. (2009). Red cell distribution width in heart failure: Prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am. Heart J. 158, 659–666. doi: 10.1016/j.ahj.2009.07.024

Gilmour, S., Menningen, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., et al. (2010). Incidence of Parkinson’s disease and atypical parkinsonism: Russian section Catalan MSA registry study.

Janoskuti, L. (2009). Red cell distribution width in heart failure: Prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state.

Kaufman, E., Hall, S., Surova, Y., Widner, H., Hansson, O., and Lindqvist, D. (2016). Serum Lymphocyte-Associated cytokine concentrations change more rapidly in progressive supranuclear palsy: A case control study. J. Neuropathol. Exp. Neurol. 75, 1233–1237. doi: 10.1007/s10072-019-04208-4

Liu, Z., Fan, Q., Wu, S., Wan, Y., and Lei, Y. (2021). Compared with the monocyte to high-density lipoprotein ratio (MDR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson’s disease. Lipids Health Dis. 20:35. doi: 10.1186/s12944-021-01462-4

Magdalíneo, N. K., Paterson, R. W., Schott, J. M., Fox, N. C., Mummery, C., Blenow, K., et al. (2015). A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurool. Neurosurg. Psychiatry 86, 1240–1247. doi: 10.1136/jnnp-2014-309562

Murphy, A. J., Chin-Dusting, J. P., Srivid, D., and Woolard, K. J. (2009). The anti inflammatory effects of high density lipoproteins. Curr. Med. Chem. 16, 667–675. doi: 10.2174/09298670978458425

Polak, D., Talar, M., Watala, C., and Przygodzki, T. (2020). Intravital assessment of blood platelet function. A review of the methodological approaches with examples of studies of selected aspects of blood platelet function. Int. J. Mol. Sci. 21, 8334. doi: 10.3390/ijms21218334

Postuma, R. R., Berg, D., Stern, M., Poeoe, W., Olanow, C. W., Oertel, W., et al. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601. doi: 10.1002/mds.26424

Rembach, A., Watt, A. D., Wilson, W. J., Rainey-Smith, S., Ellis, A. K., Rowe, C. C., et al. (2014). An increased neutrophil-lymphocyte ratio in Alzheimer’s disease is a function of age and is weakly correlated with neocortical amyloid accumulation. J. Neuroinflamm. 273, 65–71. doi: 10.1016/j.jneuroim.2014.05.005

Rydkir, B., Elving, B., Andersen, M. D., Langhol, M. A., Folkje, J., Winge, K., et al. (2017). Cytokine profiling in the prefrontal cortex of Parkinson’s Disease and Multiple System Atrophy patients. Neurol. Dis. 106, 269–278. doi: 10.1016/j.nhd.2017.07.014

Scharpica, A. H., Mann, V. M., Cooper, J. M., Kringe, D., Jenner, P. J., and Marsden, C. D. (1992). Mitochondrial function in Parkinson’s disease. The Royal Kings and Queens Parkinson’s Disease Research Group. Ann. Neurol. 32, S116–S124. doi: 10.1002/ana.410320720

Solak, Y., Yilmaz, M. I., Saglam, M., Caglar, K., Verim, S., Unal, H. U., et al. (2014). Red cell distribution width is independently related to endothelial dysfunction in patients with chronic kidney disease. Am. J. Med. Sci. 347, 118–124. doi: 10.1097/MAJ.0000000000000996

Subeta, P., Lana, A. J., and Schlachetzki, J. (2021). Chronic peripheral inflammation: A possible contributor to neurodegenerative diseases. Neuro Regen. Res. 16, 1711–1714. doi: 10.4103/1673-5374.306060

Teichbeiner, J. Z., Nutman, A., Boursi, B., Shlomi, A., Sella, T., Wasserman, A., et al. (2011). Diagnostic and prognostic value of thrombocytosis in admitted medical patients. Am. J. Med. Sci. 342, 395–401. doi: 10.1097/MAJ.0b013e3182147f6d

Wang, H., Xu, H., Wang, X., Wu, R., Gao, X., Qin, J., et al. (2016). Red blood cell distribution width to platelet ratio is related to histologic severity of primary biliary cirrhosis. Medecine 95:e3114. doi: 10.1053/j.medi.2016.10.003

Williams, G. P., Marmion, D. J., Schonhoff, A. M., Jurkuvenaite, A., Won, W. J., Standaert, D. G., et al. (2020). T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. Acta Neuropathol. 139, 855–874. doi: 10.1007/s00401-020-02126-w

Winter, Y., Besderodny, Y., Katunina, E., Avjakian, G., Reese, J. P., Klotzsche, J., et al. (2010). Incidence of Parkinson’s disease and atypical parkinsonism: Russian population-based study. Mov. Disord. 25, 349–356. doi: 10.1002/mds.22966

Yamasaki, R., Yamaguchi, H., Matsushita, T., Fujii, T., Hiwatashi, A., and Kira, J. I. (2017). Early strong intrathecal inflammation in cerebellar type multiple system atrophy by cerebrospinal fluid cytokine/chemokine profiles: A case control study. J. Neuroimmunol. 319:776–781. doi: 10.1016/j.jneumedi.2017.09.007

Ziegler-Heitbrock, L. (2007). The CD14+ CD16+ blood monocytes: Their role in infection and inflammation. J. Leukoc. Biol. 81, 584–592. doi: 10.1189/jlb.0806510
## Appendix

APPENDIX 1 Baseline information for multiple system atrophy cerebellar type (MSA-C) and multiple system atrophy-parkinsonism (MSA-P).

|                     | MSA-C (n = 27) | MSA-P (n = 20) | Z/T   | P    |
|---------------------|----------------|----------------|-------|------|
| Age (years)         | 60 (54–66)     | 61 (56–65.75)  | −0.356| 0.722|
| Sex (male, %)       | 18 (63.8%)     | 72 (57.6%)     | 0.221 | 0.638|
| Smoking (%)         | 5 (10.6%)      | 10 (8%)        | 4.145 | 0.042|
| Drinking (%)        | 7 (14.9%)      | 12 (9.6%)      | 0.658 | 0.417|
| Hypertension (%)    | 12 (25.5%)     | 19 (15.2%)     | 1.641 | 0.200|
| Disease duration (month) | 12 (8–24) | 24 (8.25–45)  | −1.392| 0.164|